Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW | ISIN: KYG2588M1006 | Ticker-Symbol: PH4
Frankfurt
27.06.25 | 15:29
0,450 Euro
-5,46 % -0,026
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,4460,47220:36
0,4460,46620:36

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiCSTONE PHARMA-B (02616): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE2
MiCSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION3
MiCSTONE PHARMA-B (02616): (1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025; (2) RETIREMENT AND RESIGNATION OF DIRECTORS; AND (3) CHANGE ...2
19.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - LONG-TERM SURVIVAL DATA OF GEMSTONE-302 TRIAL ON SUGEMALIMAB PUBLISHED IN THE LANCET ONCOLOGY7
13.06.CSTONE PHARMA-B (02616): ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES3
03.06.CSTONE PHARMA-B (02616): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR AND ...6
03.06.CSTONE PHARMA-B (02616): FORM OF PROXY FOR ANNUAL GENERAL MEETING1
03.06.CSTONE PHARMA-B (02616): NOTICE OF ANNUAL GENERAL MEETING-
06.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTED FIVE LATEST STUDIES AT 2025 AACR ANNUAL MEETING4
28.04.CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20242
28.04.CSTONE PHARMA-B (02616): 2024 ANNUAL REPORT4
11.04.CSTONE PHARMA-B (02616): (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP1
10.04.CSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN2
10.04.CSTONE PHARMA-B (02616): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE3
09.04.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 560,000 SHARES, WITH ...3
02.04.CSTONE PHARMA-B (02616): PLACING OF NEW SHARES UNDER GENERAL MANDATE17
27.03.CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress162Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ...
► Artikel lesen
27.03.CSTONE PHARMA-B (02616): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 20242
26.03.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE TO SHOWCASE FIVE LATEST RESEARCH ACHIEVEMENTS AT AACR 20254
24.03.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE SUBMITS APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR NEW INDICATION OF SUGEMALIMAB IN STAGE ...2
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1